🔎 Trials Near Me

Utama › Neoplasma Mengikut Jenis Histologi › Georgia

Kajian klinikal Neoplasma Mengikut Jenis Histologi di Georgia

6 kajian untuk Neoplasma Mengikut Jenis Histologi sedang mencari peserta di lokasi di Georgia.

Bandar di Georgia

Teks kajian rasmi (Bahasa Inggeris)

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

  • Emory University Hospital, Atlanta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT07075185

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Emory Healthcare - The Emory Clinic, Atlanta
  • Georgia Cancer Center at Augusta University, Augusta
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06001788

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • Winship Cancer Institute of Emory University, Atlanta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 19 Ogo 2026 · NCT04104776

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • Winship Cancer Institute - Emory University, Atlanta
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT04198766

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

  • University Cancer and Blood Center, Athens
Mengambil pesertaFasa 1/2
Umur 12 ke atas · Semua jantina · Dikemas kini 27 Mei 2026 · NCT03093116

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

  • Northside Hospital, Atlanta
Mengambil pesertaFasa 1
Umur 18 hingga 75 · Semua jantina · Dikemas kini 2 Ogo 2024 · NCT06271252

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.